Research map: Biomarker implications of gene editing in hematologic diseases: latest updates from ASH 2025

Back to the article

Papers in this map

  1. Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE) · Jia Chen · 2025 · 3 citations · Cited by this paper
  2. 3D bioprinting for cancer modeling and drug screening · 2026 · Related
  3. In Vivo hematopoietic stem cell (HSC) engineering and selection with CD90-targeted multiplexed virus-like particles (MVPs) for HSC gene therapy and cancer immunotherapy · Stefan Radtke · 2025 · 3 citations · Cited by this paper
  4. Microbial, functional, and virulence biomarkers associated with familial risk of Crohn’s disease and ulcerative colitis · 2026 · Related
  5. Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study · Ashish V Gupta · 2025 · 2 citations · Cited by this paper
  6. CD163+ macrophages coordinate erythroblastic Island formation and iron metabolism to enable glucocorticoid-induced erythropoiesis · 2026 · Related
  7. Long-term follow-up of the first in human post-transcriptional genetic silencing of BCL11A in sickle cell disease in a phase 1 pilot and feasibility trial · Erica B. Esrick · 2025 · 2 citations · Cited by this paper
  8. Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models · 2026 · Related
  9. In Vivo correction of the sickle cell disease mutation in hematopoietic stem cells using RNA gene writers · Yaser Heshmati · 2025 · 2 citations · Cited by this paper
  10. Predictive value of lipopolysaccharide for cerebral-cardiac syndrome, stroke-associated pneumonia, and prognosis in acute ischemic stroke · 2026 · Related
  11. CRISPR-Cas12a gene editing of the HBG1/2 promoters leads to sustained normalization of total hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease: Updated Results from the RUBY trial · Rabi Hanna · 2025 · 2 citations · Cited by this paper
  12. Single-cell and spatial transcriptome analysis reveals the potential therapeutic targets for testicular sex cord-stromal cell tumor · 2026 · Related
  13. Efficient prime editing of human hematopoietic stem cells corrects the recurrent SBDS C.258+2T>C mutation and recovers engraftment potential in shwachman-diamond syndrome · Gue‐Ho Hwang · 2025 · 2 citations · Cited by this paper
  14. Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH · 2026 · Related
  15. Silencing of BCL11A by disrupting enhancer-dependent epigenetic insulation · Kaili Wang · 2025 · 1 citation · Cited by this paper
  16. EGF as a non-invasive biomarker of endometriosis: a case control study · 2026 · Related
  17. Toward ‘n of one’ gene therapies: Scalable ex vivo adenine base editing via lipid nanoparticles in a sickle cell disease model · Sarah A. Cotteta · 2025 · 1 citation · Cited by this paper
  18. Emerging applications of long-read sequencing in hematological malignancies: highlights from the 2025 ASH annual meeting · 2026 · Related
  19. Early post-marketing safety signals of CRISPR-edited exagamglogene autotemcel (Casgevy) versus lentiviral betibeglogene autotemcel (Zynteglo): A faers disproportionality study, 2014–2025 · Aftab A. Ahmed · 2025 · 1 citation · Cited by this paper
  20. Cell death crosstalk in NET-Driven inflammation: mechanisms, disease contexts, and therapeutic perspectives · 2026 · Related
  21. Evaluating the efficacy and safety of gene therapy in transfusion-dependent β-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring · Gonzalo De Luna · 2025 · 1 citation · Cited by this paper
  22. Expansion of human hematopoietic stem cells by inhibiting translation · C Y Li · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)